We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
QIAGEN Launches QIAsymphony SP Device Outside the U.S.
Read MoreHide Full Article
Molecular diagnostics major QIAGEN N.V. (QGEN - Free Report) recently announced the launch of QIAsymphony SP instrument as a front-end option for sample processing for its GeneReader NGS System outside the U.S. The GeneReader NGS workflow can now integrate with the system, allowing laboratories to perform processing of different samples. The processing and analysis is done to gain valuable molecular insights from samples comprising DNA, RNA and proteins from blood, tissue and other materials.
The GeneReader NGS workflow was launched by Qiagen last year. It is the world’s first complete Sample to Insight NGS (Next Generation Sequencing) solution designed for the delivery of actionable insights. NGS helps labs gain valuable molecular insights but has downsides such as high cost and fragmented workflow. The GeneReader NGS accurately identifies genetic markers (genes or DNA sequences) associated with approved therapies, leading professional guidelines and active clinical trials. It is presently available for sale outside the U.S.
QIAsymphony SP helps non U.S. labs perform sample processing with any difficulty. The instrument offers processing with continuous loading of up to 96 samples and proven protocols to process and purify samples for analysis. QIAsymphony SP is registered with the FDA and is part of workflows approved by the agency. It also offers advanced process control and integrates with Laboratory Information Management Systems (LIMS). The device is currently available for processing tissue samples for the GeneReader NGS System.
Management at QIAGEN is encouraged by the adoption of GeneReader NGS System as a user-friendly solution for next-generation sequencing. The company feels that the adding of QIAsymphony SP instrument to the GeneReader NGS System would lead to higher throughput workflow. Compared to the previoys QIAcube, which automates lower throughput sample processing, the new instrument can handle different sample volumes and types efficiently for GeneReader NGS users.
Per a Grand View Research report, the global molecular diagnostics market is expected to reach a value of over $17.9 billion by 2024. To tap into the potential of this growing market, QIAGEN is developing technologies for sample processing to enable customers to gain valuable insights of samples. Earlier this year, the company added an advanced control package with verification data to support the proven accuracy of GeneReader NGS and to facilitate system set-up, quality assurance and training for labs. The GeneRead Actionable Insights Tumor Panel, for detection of mutations in 12 genes, was optimized for researching both non-invasive liquid biopsies and FFPE tissue samples. Presently, QIAGEN is developing specialized panels to run on GeneReader NGS outside the U.S. to meet clinical research needs for lung and breast cancer.
Key Picks
A few notable stocks in the medical product sector are Quidel Corp. (QDEL - Free Report) , NuVasive, Inc. and GW Pharmaceuticals plc .
Quidel is expected to record earnings growth of 20%, higher than the industry average of 14.8% over the next five years. It has a four-quarter average earning surprise of 59.39%.
NuVasive has a trailing four-quarter average earning surprise of 18.98%. For the past five years, the stock saw a 16.6% earnings growth compared to the industry average of 5%.
GW Pharmaceuticals has a four-quarter average earning surprise of 41.67%.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
QIAGEN Launches QIAsymphony SP Device Outside the U.S.
Molecular diagnostics major QIAGEN N.V. (QGEN - Free Report) recently announced the launch of QIAsymphony SP instrument as a front-end option for sample processing for its GeneReader NGS System outside the U.S. The GeneReader NGS workflow can now integrate with the system, allowing laboratories to perform processing of different samples. The processing and analysis is done to gain valuable molecular insights from samples comprising DNA, RNA and proteins from blood, tissue and other materials.
The GeneReader NGS workflow was launched by Qiagen last year. It is the world’s first complete Sample to Insight NGS (Next Generation Sequencing) solution designed for the delivery of actionable insights. NGS helps labs gain valuable molecular insights but has downsides such as high cost and fragmented workflow. The GeneReader NGS accurately identifies genetic markers (genes or DNA sequences) associated with approved therapies, leading professional guidelines and active clinical trials. It is presently available for sale outside the U.S.
QIAsymphony SP helps non U.S. labs perform sample processing with any difficulty. The instrument offers processing with continuous loading of up to 96 samples and proven protocols to process and purify samples for analysis. QIAsymphony SP is registered with the FDA and is part of workflows approved by the agency. It also offers advanced process control and integrates with Laboratory Information Management Systems (LIMS). The device is currently available for processing tissue samples for the GeneReader NGS System.
QIAGEN NV Price
QIAGEN NV Price | QIAGEN NV Quote
Management at QIAGEN is encouraged by the adoption of GeneReader NGS System as a user-friendly solution for next-generation sequencing. The company feels that the adding of QIAsymphony SP instrument to the GeneReader NGS System would lead to higher throughput workflow. Compared to the previoys QIAcube, which automates lower throughput sample processing, the new instrument can handle different sample volumes and types efficiently for GeneReader NGS users.
Per a Grand View Research report, the global molecular diagnostics market is expected to reach a value of over $17.9 billion by 2024. To tap into the potential of this growing market, QIAGEN is developing technologies for sample processing to enable customers to gain valuable insights of samples. Earlier this year, the company added an advanced control package with verification data to support the proven accuracy of GeneReader NGS and to facilitate system set-up, quality assurance and training for labs. The GeneRead Actionable Insights Tumor Panel, for detection of mutations in 12 genes, was optimized for researching both non-invasive liquid biopsies and FFPE tissue samples. Presently, QIAGEN is developing specialized panels to run on GeneReader NGS outside the U.S. to meet clinical research needs for lung and breast cancer.
Key Picks
A few notable stocks in the medical product sector are Quidel Corp. (QDEL - Free Report) , NuVasive, Inc. and GW Pharmaceuticals plc .
Quidel is expected to record earnings growth of 20%, higher than the industry average of 14.8% over the next five years. It has a four-quarter average earning surprise of 59.39%.
NuVasive has a trailing four-quarter average earning surprise of 18.98%. For the past five years, the stock saw a 16.6% earnings growth compared to the industry average of 5%.
GW Pharmaceuticals has a four-quarter average earning surprise of 41.67%.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>